Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Johnson-and-Johnson stock | $147.11

Own Johnson-and-Johnson stock in just a few minutes.

Updated

Fact checked

Johnson & Johnson is a drug manufacturers—general business based in the US. Johnson-and-Johnson shares (JNJ) are listed on the NYSE and all prices are listed in US Dollars. Johnson-and-Johnson employs 132,200 staff and has a trailing 12-month revenue of around USD$80.5 billion.

How to buy shares in Johnson-and-Johnson

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Johnson-and-Johnson Find the stock by name or ticker symbol: JNJ. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Johnson-and-Johnson reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$147.11, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Johnson-and-Johnson, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Johnson-and-Johnson. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Johnson-and-Johnson share price

Use our graph to track the performance of JNJ stocks over time.

Johnson-and-Johnson shares at a glance

Information last updated 2020-09-25.
Latest market closeUSD$147.11
52-week rangeUSD$109.16 - USD$157
50-day moving average USD$149.3292
200-day moving average USD$144.5778
Wall St. target priceUSD$165.06
PE ratio 25.3849
Dividend yield USD$4.04 (2.8%)
Earnings per share (TTM) USD$5.684

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
TD Ameritrade
Stocks,Bonds,Options,Mutual funds,ETFs,Forex,Futures
$0
or $25 If it is broker-assisted
$0 + $0.65/contract,
or $25 Broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Johnson-and-Johnson stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Johnson-and-Johnson price performance over time

Historical closes compared with the close of $147.11 from 2020-09-28

1 week (2020-09-23) 1.85%
1 month (2020-08-28) -4.25%
3 months (2020-06-30) 4.61%
6 months (2020-03-30) 10.60%
1 year (2019-09-30) 13.70%
2 years (2018-09-28) 6.47%
3 years (2017-09-29) 13.15%
5 years (2015-09-30) 57.59%

Is Johnson-and-Johnson under- or over-valued?

Valuing Johnson-and-Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson-and-Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Johnson-and-Johnson's P/E ratio

Johnson-and-Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Johnson-and-Johnson shares trade at around 25x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Johnson-and-Johnson's PEG ratio

Johnson-and-Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.126. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson-and-Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Johnson-and-Johnson's EBITDA

Johnson-and-Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$27.2 billion.

The EBITDA is a measure of a Johnson-and-Johnson's overall financial performance and is widely used to measure a its profitability.

Johnson-and-Johnson financials

Revenue TTM USD$80.5 billion
Operating margin TTM 25.09%
Gross profit TTM USD$54.6 billion
Return on assets TTM 8.05%
Return on equity TTM 24.54%
Profit margin 18.86%
Book value $23.924
Market capitalisation USD$391.8 billion

TTM: trailing 12 months

Shorting Johnson-and-Johnson shares

There are currently 10.6 million Johnson-and-Johnson shares held short by investors – that's known as Johnson-and-Johnson's "short interest". This figure is 14.8% down from 12.4 million last month.

There are a few different ways that this level of interest in shorting Johnson-and-Johnson shares can be evaluated.

Johnson-and-Johnson's "short interest ratio" (SIR)

Johnson-and-Johnson's "short interest ratio" (SIR) is the quantity of Johnson-and-Johnson shares currently shorted divided by the average quantity of Johnson-and-Johnson shares traded daily (recently around 5.4 million). Johnson-and-Johnson's SIR currently stands at 1.96. In other words for every 100,000 Johnson-and-Johnson shares traded daily on the market, roughly 1960 shares are currently held short.

However Johnson-and-Johnson's short interest can also be evaluated against the total number of Johnson-and-Johnson shares, or, against the total number of tradable Johnson-and-Johnson shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson-and-Johnson's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Johnson-and-Johnson shares in existence, roughly 0 shares are currently held short) or 0.004% of the tradable shares (for every 100,000 tradable Johnson-and-Johnson shares, roughly 4 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Johnson-and-Johnson.

Find out more about how you can short Johnson-and-Johnson stock.

Johnson-and-Johnson's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson-and-Johnson.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Johnson-and-Johnson's total ESG risk score

Total ESG risk: 35.78

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson-and-Johnson's overall score of 35.78 (as at 08/01/2020) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Johnson-and-Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Johnson-and-Johnson's environmental score

Environmental score: 3.79/100

Johnson-and-Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Johnson-and-Johnson's social score

Social score: 25.14/100

Johnson-and-Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Johnson-and-Johnson's governance score

Governance score: 15.85/100

Johnson-and-Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson-and-Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Johnson-and-Johnson's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson-and-Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson-and-Johnson has a damaged public profile.

Environmental, social, and governance (ESG) summary

Johnson & Johnson was last rated for ESG on: 2020-08-01.

Total ESG score 35.78
Total ESG percentile 72.34
Environmental score 3.79
Environmental score percentile 7
Social score 25.14
Social score percentile 7
Governance score 15.85
Governance score percentile 7
Level of controversy 4

Johnson-and-Johnson share dividends

68%

Dividend payout ratio: 67.84% of net profits

Recently Johnson-and-Johnson has paid out, on average, around 67.84% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.8% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson-and-Johnson shareholders could enjoy a 2.8% return on their shares, in the form of dividend payments. In Johnson-and-Johnson's case, that would currently equate to about $4.04 per share.

Johnson-and-Johnson's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Johnson-and-Johnson's most recent dividend payout was on 8 September 2020. The latest dividend was paid out to all shareholders who bought their shares by 24 August 2020 (the "ex-dividend date").

Have Johnson-and-Johnson's shares ever split?

Johnson-and-Johnson's shares were split on a 2:1 basis on 13 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson-and-Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson-and-Johnson shares which in turn could have impacted Johnson-and-Johnson's share price.

Johnson-and-Johnson share price volatility

Over the last 12 months, Johnson-and-Johnson's shares have ranged in value from as little as $109.16 up to $157. A popular way to gauge a stock's volatility is its "beta".

JNJ.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson-and-Johnson's is 0.6817. This would suggest that Johnson-and-Johnson's shares are less volatile than average (for this exchange).

Johnson-and-Johnson overview

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site